Cytokinetics, Incorporated Cytokinetics, Incorporated

Cytokinetics, Incorporated

CYTK

Classificação em ações #2266
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on... Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Preço da ação
$63.98
Valor de mercado
$8.89B
Variação (1 dia)
2.12%
Variação (1 ano)
7.80%
País
US
Negociar Cytokinetics, Incorporated (CYTK)

Categoria

Healthcare
Histórico de desdobramentos de ações de Cytokinetics, Incorporated (CYTK)
As ações Cytokinetics, Incorporated (símbolo: CYTK) passaram por um total de 1 desdobramentos.
O desdobramento mais recente ocorreu em Jun 25, 2013.
Uma ação CYTK comprada antes de Jun 25, 2013 equivaleria hoje a 0.16666666666667 ações CYTK.
Lista de desdobramentos de ações
Ano Desdobramento Multiplicador Multiplicador cumulativo
2013-06-25 1:6 x0.16666666666667 x0.16666666666667
Desdobramentos de ações de empresas semelhantes ou concorrentes
Empresa Número de desdobramentos de ações Multiplicador cumulativo País
1 x2
US
0 -
US
1 x3
AU
0 -
CH
0 -
NL